Loss of Dnmt3a increases self-renewal and resistance to pegIFNα in JAK2-V617F-positive myeloproliferative neoplasms

被引:3
|
作者
Usart, Marc [1 ,2 ]
Stetka, Jan [1 ,2 ,3 ]
Paz, Damien Luque [4 ]
Hansen, Nils [1 ,2 ]
Kimmerlin, Quentin [1 ,2 ]
Fonseca, Tiago Almeida [1 ,2 ]
Lock, Melissa [1 ,2 ]
Kubovcakova, Lucia [1 ,2 ]
Karjalainen, Riikka [1 ,2 ]
Hao-Shen, Hui [1 ,2 ]
Boersch, Anastasiya [5 ,6 ,7 ]
El Taher, Athimed [5 ,6 ,7 ,8 ]
Schulz, Jessica [8 ]
Leroux, Jean-Christophe [8 ]
Dirnhofer, Stefan [9 ]
Skoda, Radek C. [1 ,2 ]
机构
[1] Univ Basel Hosp, Dept Biomed, Expt Hematol, Hebelstr 20, CH-4031 Basel, Switzerland
[2] Univ Basel, Hebelstr 20, CH-4031 Basel, Switzerland
[3] Palacky Univ, Fac Med & Dent, Dept Biol, Olomouc, Czech Republic
[4] Univ Angers, Nantes Univ, Ctr Hosp Univ Angers, Ctr Natl Rech Sci,Ctr Rech Cancerol & Immunol Inte, Angers, France
[5] Univ Basel, Dept Biomed, Bioinformat, Basel, Switzerland
[6] Univ Hosp Basel, Basel, Switzerland
[7] Swiss Inst Bioinformat, Basel, Switzerland
[8] ETH Honggerberg Zurich, Inst Pharmaceut Sci, Zurich, Switzerland
[9] Univ Hosp Basel, Inst Med Genet & Pathol, Basel, Switzerland
基金
瑞士国家科学基金会;
关键词
HEMATOPOIETIC STEM-CELLS; CLONAL HEMATOPOIESIS; POLYCYTHEMIA-VERA; INTERFERON-ALPHA; T-CELLS; MUTATIONS; JAK2-V617F; CLASSIFICATION; EXPRESSION; PROGNOSIS;
D O I
10.1182/blood.2023020270
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pegylated interferon alfa (pegIFN- alpha ) can induce molecular remissions in patients with JAK2 -V617F-positive myeloproliferative neoplasms (MPNs) by targeting long-term hematopoietic stem cells (LT-HSCs). Additional somatic mutations in genes regulating LT-HSC self-renewal, such as DNMT3A , have been reported to have poorer responses to pegIFN alpha . We investigated whether DNMT3A loss leads to alterations in JAK2 -V617F LTHSC functions conferring resistance to pegIFN alpha treatment in a mouse model of MPN and in hematopoietic progenitors from patients with MPN. Long -term treatment with pegIFN alpha normalized blood parameters and reduced splenomegaly and JAK2 -V617F chimerism in single -mutant JAK2 -V617F ( VF ) mice. However, pegIFN alpha in VF ; Dnmt3a Delta / Delta ( VF;Dm Delta / Delta ) mice worsened splenomegaly and failed to reduce JAK2 -V617F chimerism. Furthermore, LT-HSCs from VF;Dm Delta / Delta mice compared with VF were less prone to accumulate DNA damage and exit dormancy upon pegIFN alpha treatment. RNA sequencing showed that IFN alpha induced stronger upregulation of in fl ammatory pathways in LT-HSCs from VF;Dm Delta / Delta than from VF mice, indicating that the resistance of VF;Dm Delta / Delta LT-HSC was not due tofailure in IFN alpha signaling. Transplantations of bone marrow from pegIFN alpha - treated VF;Dm Delta / Delta mice gave rise to more aggressive disease in secondary and tertiary recipients. Liquid cultures of hematopoietic progenitors from patients with MPN with JAK2 -V617F and DNMT3A mutation showed increased percentages of JAK2 -V617F-positive colonies upon IFN alpha exposure, whereas in patients with JAK2 -V617F alone, the percentages of JAK2 -V617F-positive colonies decreased or remained unchanged. PegIFN- alpha combined with 5-azacytidine only partially overcame resistance in VF;Dm Delta / Delta mice. However, this combination strongly decreased the JAK2 -mutant allele burden in mice carrying VF mutation only, showing potential to in fl ict substantial damage preferentially to the JAK2 -mutant clone.
引用
收藏
页码:2490 / 2503
页数:14
相关论文
共 50 条
  • [1] Molecular analysis of phenotypic heterogeneity in JAK2V617F-positive myeloproliferative neoplasms reveals a potential target for therapy
    Gu, Wenjing
    Tong, Jingyuan
    Fu, Rongfeng
    Sun, Ting
    Ju, Mankai
    Zhao, Yanhong
    Wang, Di
    Gao, Jie
    Liu, Jinhua
    Gao, Yuchen
    Li, Huiyuan
    Wang, Wentian
    Chi, Ying
    Yang, Renchi
    Chen, Lu
    Shi, Lihong
    Zhang, Lei
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (04) : 690 - 703
  • [2] The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms
    Holmstrom, M. O.
    Hjortso, M. D.
    Ahmad, S. M.
    Met, O.
    Martinenaite, E.
    Riley, C.
    Straten, P.
    Svane, I. M.
    Hasselbalch, H. C.
    Andersen, M. H.
    LEUKEMIA, 2017, 31 (02) : 495 - 498
  • [3] Mutation Analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese Patients with Myeloproliferative Neoplasms
    Wang, Min
    He, Na
    Tian, Tian
    Liu, Lu
    Yu, Shuang
    Ma, Daoxin
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [4] JAK2-V617F Mutation and BCR-ABL Rearrangement in Chronic Myeloproliferative Neoplasms
    Zahra, M. K.
    El-Fadaly, N. H.
    Aboul-Enein, K. M.
    Elgamal, B. M.
    Abd El-Naby, Amira Y.
    Amer, Eman A.
    LIFE SCIENCE JOURNAL-ACTA ZHENGZHOU UNIVERSITY OVERSEAS EDITION, 2012, 9 (02): : 403 - 414
  • [5] Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms
    Zhang, Shu-Peng
    Li, Hui
    Lai, Ren-Sheng
    ONCOLOGY LETTERS, 2015, 9 (02) : 735 - 738
  • [6] Analysis of JAK2 V617F mutation in Tunisian patients with myeloproliferative neoplasms
    Chadi, Soumaya
    Dhaouadi, Tarak
    Sfar, Imen
    Baccouche, Hela
    Nabli, Rym
    Ben Romdhane, Neila
    Ben Abdallah, Taieb
    Gorgi, Yousr
    EUROPEAN JOURNAL OF INFLAMMATION, 2021, 19
  • [7] Thrombosis in Myeloproliferative Neoplasms With JAK2V617F Mutation
    Sun, Tiantian
    Zhang, Lei
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2013, 19 (04) : 374 - 381
  • [8] Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms
    Zhao, Baobing
    Mei, Yang
    Cao, Lan
    Zhang, Jingxin
    Sumagin, Ronen
    Yang, Jing
    Gao, Juehua
    Schipma, Matthew J.
    Wang, Yanfeng
    Thorsheim, Chelsea
    Zhao, Liang
    Stalker, Timothy
    Stein, Brady
    Wen, Qiang Jeremy
    Crispino, John D.
    Abrams, Charles S.
    Ji, Peng
    JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (01): : 125 - 140
  • [9] Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms
    Bernard, L.
    Belisle, C.
    Mollica, L.
    Provost, S.
    Roy, D-C
    Gilliland, D. G.
    Levine, R. L.
    Busque, L.
    LEUKEMIA, 2009, 23 (02) : 287 - 291
  • [10] The relevance of HLA class II genes in JAK2 V617F-positive myeloproliferative neoplasms
    Shivarov, Velizar
    Tsvetkova, Gergana
    Hadjiev, Evgueniy
    Ivanova, Milena
    HUMAN IMMUNOLOGY, 2023, 84 (03) : 199 - 207